CELDOXOME PEGYLATED LIPOSOMAL Concentrate for dispersion for infusion Ref.[50675] Active ingredients: Doxorubicin

Source: European Medicines Agency (EU)  Revision Year: 2023  Publisher: YES Pharmaceutical Development Services GmbH, Bahnstraße 42-46, 61381 Friedrichsdorf, Germany

4.3. Contraindications

Hypersensitivity to the active substance, peanut or soya, or to any of the excipients listed in section 6.1.

Celdoxome pegylated liposomal must not be used to treat AIDS-KS that may be treated effectively with local therapy or systemic alfa-interferon.

4.4. Special warnings and precautions for use

Given the difference in pharmacokinetic profiles and dosing schedules, Celdoxome pegylated liposomal should not be used interchangeably with other formulations of doxorubicin hydrochloride.

Cardiac toxicity

It is recommended that all patients receiving liposomal doxorubicin routinely undergo frequent ECG monitoring. Transient ECG changes such as T-wave flattening, S-T segment depression and benign arrhythmias are not considered mandatory indications for the suspension of a liposomal doxorubicin therapy. However, reduction of the QRS complex is considered more indicative of cardiac toxicity. If this change occurs, the most definitive test for anthracycline myocardial injury, i.e., endomyocardial biopsy, must be considered.

More specific methods for the evaluation and monitoring of cardiac functions as compared to ECG are a measurement of left ventricular ejection fraction by echocardiography or preferably by Multigated Angiography (MUGA). These methods must be applied routinely before the initiation of a liposomal doxorubicin therapy and repeated periodically during treatment. The evaluation of left ventricular function is considered to be mandatory before each additional administration of liposomal doxorubicin that exceeds a lifetime cumulative anthracycline dose of 450 mg/m².

The evaluation tests and methods mentioned above concerning the monitoring of cardiac performance during anthracycline therapy are to be employed in the following order: ECG monitoring, measurement of left ventricular ejection fraction, endomyocardial biopsy. If a test result indicates possible cardiac injury associated with liposomal doxorubicin therapy, the benefit of continued therapy must be carefully weighed against the risk of myocardial injury.

In patients with cardiac disease requiring treatment, liposomal doxorubicin should only be administered when the benefit outweighs the risk to the patient.

Caution should be exercised in patients with impaired cardiac function who receive liposomal doxorubicin.

Whenever cardiomyopathy is suspected, i.e., the left ventricular ejection fraction has substantially decreased relative to pre-treatment values and/or left ventricular ejection fraction is lower than a prognostically relevant value (e.g., <45%), endomyocardial biopsy may be considered and the benefit of continued therapy must be carefully evaluated against the risk of developing irreversible cardiac damage.

Congestive heart failure due to cardiomyopathy may occur suddenly, without prior ECG changes and may also be encountered several weeks after discontinuation of therapy.

Caution must be observed in patients who have received other anthracyclines. The total dose of doxorubicin hydrochloride must also take into account any previous (or concomitant) therapy with cardiotoxic compounds such as other anthracyclines/anthraquinones or e.g., 5-fluorouracil. Cardiac toxicity also may occur at cumulative anthracycline doses lower than 450 mg/m² in patients with prior mediastinal irradiation or in those receiving concurrent cyclophosphamide therapy.

The cardiac safety profile for the dosing schedule recommended for both breast and ovarian cancer (50 mg/m²) is similar to the 20 mg/m² profile in patients with AIDS-KS (see section 4.8).

Myelosuppression

Many patients treated with liposomal doxorubicin have baseline myelosuppression due to such factors as their pre-existing HIV disease or numerous concomitant or previous medicinal product, or tumours involving bone marrow. In the pivotal trial in patients with ovarian cancer treated at a dose of 50 mg/m², myelosuppression was generally mild to moderate, reversible, and was not associated with episodes of neutropaenic infection or sepsis. Moreover, in a controlled clinical trial of liposomal doxorubicin vs. topotecan, the incidence of treatment related sepsis was substantially less in the liposomal doxorubicin-treated ovarian cancer patients as compared to the topotecan treatment group. A similar low incidence of myelosuppression was seen in patients with metastatic breast cancer receiving liposomal doxorubicin in a first-line clinical trial. In contrast to the experience in patients with breast cancer or ovarian cancer, myelosuppression appears to be the dose-limiting adverse event in patients with AIDS-KS (see section 4.8). Because of the potential for bone marrow suppression, periodic blood counts must be performed frequently during the course of a liposomal doxorubicin therapy, and at a minimum, prior to each dose of liposomal doxorubicin.

Persistent severe myelosuppression may result in superinfection or haemorrhage.

In controlled clinical trials in patients with AIDS-KS against a bleomycin/vincristine regimen, opportunistic infections were apparently more frequent during treatment with liposomal doxorubicin. Patients and doctors must be aware of this higher incidence and take action as appropriate.

Secondary haematological malignancies

As with other DNA-damaging antineoplastic agents, secondary acute myeloid leukemias and myelodysplasias have been reported in patients having received combined treatment with doxorubicin. Therefore, any patient treated with doxorubicin should be kept under haematological supervision. Secondary oral neoplasms Very rare cases of secondary oral cancer have been reported in patients with long-term (more than one year) exposure to liposomal doxorubicin or those receiving a cumulative liposomal doxorubicin dose greater than 720 mg/m². Cases of secondary oral cancer were diagnosed both, during treatment with liposomal doxorubicin, and up to 6 years after the last dose. Patients should be examined at regular intervals for the presence of oral ulceration or any oral discomfort that may be indicative of secondary oral cancer.

Infusion-associated reactions

Serious and sometimes life-threatening infusion reactions, which are characterised by allergic-like or anaphylactoid-like reactions, with symptoms including asthma, flushing, urticarial rash, chest pain, fever, hypertension, tachycardia, pruritus, sweating, shortness of breath, facial oedema, chills, back pain, tightness in the chest and throat and/or hypotension may occur within minutes of starting the infusion of Celdoxome pegylated liposomal. Very rarely, convulsions also have been observed in relation to infusion reactions. Temporarily stopping the infusion usually resolves these symptoms without further therapy. However, medications to treat these symptoms (e.g., antihistamines, corticosteroids, adrenaline, and anticonvulsants), as well as emergency equipment should be available for immediate use. In most patients treatment can be resumed after all symptoms have resolved, without recurrence. Infusion reactions rarely recur after the first treatment cycle. To minimise the risk of infusion reactions, the initial dose should be administered at a rate no greater than 1 mg/minute (see section 4.2).

Palmar plantar erythrodysaesthesia syndrome (PPE)

PPE is characterised by painful, macular reddening skin eruptions. In patients experiencing this event, it is generally seen after two or three cycles of treatment. Improvement usually occurs in 1–2 weeks, and in some cases, may take up to 4 weeks or longer for complete resolution. Pyridoxine at a dose of 50-150 mg per day and corticosteroids have been used for the prophylaxis and treatment of PPE, however, these therapies have not been evaluated in phase III trials. Other strategies to prevent and treat PPE include keeping hands and feet cool, by exposing them to cool water (soaks, baths, or swimming), avoiding excessive heat/hot water and keeping them unrestricted (no socks, gloves, or shoes that are tight fitting). PPE appears to be primarily related to the dose schedule and can be reduced by extending the dose interval 1-2 weeks (see section 4.2). However, this reaction can be severe and debilitating in some patients and may require discontinuation of treatment (see section 4.8).

Extravasation

Although local necrosis following extravasation has been reported very rarely, Celdoxome pegylated liposomal is considered to be an irritant. Animal studies indicate that administration of doxorubicin hydrochloride as a liposomal formulation reduces the potential for extravasation injury. If any signs or symptoms of extravasation occur (e.g., stinging, erythema) the infusion must be terminated immediately and restarted in another vein. The application of ice over the site of extravasation for approximately 30 minutes may be helpful in alleviating the local reaction. Celdoxome pegylated liposomal must not be given by the intramuscular or subcutaneous route.

Diabetic patients

Please note that each vial of Celdoxome pegylated liposomal contains sucrose and the dose is administered in 5% (50 mg/mL) glucose solution for infusion.

For common adverse events which required dose modification or discontinuation see section 4.8.

Excipients

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium-free’.

4.5. Interaction with other medicinal products and other forms of interaction

No formal medicinal product interaction studies have been performed with liposomal doxorubicin, although phase II combination trials with conventional chemotherapy agents have been conducted in patients with gynaecological malignancies. Caution in the concomitant use of medicinal products known to interact with standard doxorubicin hydrochloride must be exercised. Celdoxome pegylated liposomal, like other doxorubicin hydrochloride preparations, may potentiate the toxicity of other anticancer therapies. During clinical trials in patients with solid tumours (including breast and ovarian cancer) who have received concomitant cyclophosphamide or taxanes, no new additive toxicities were noted. In patients with AIDS, exacerbation of cyclophosphamide-induced haemorrhagic cystitis and enhancement of the hepatotoxicity of 6-mercaptopurine have been reported with standard doxorubicin hydrochloride. Caution must be exercised when giving any other cytotoxic agents, especially myelotoxic agents, at the same time.

4.6. Fertility, pregnancy and lactation

Women of child-bearing potential

Women of child-bearing potential must be advised to avoid pregnancy while they or their male partner are receiving Celdoxome pegylated liposomal and in the six months following discontinuation of Celdoxome pegylated liposomal therapy (see section 5.3).

Pregnancy

Doxorubicin hydrochloride is suspected to cause serious birth defects when administered during pregnancy. Therefore, Celdoxome pegylated liposomal should not be used during pregnancy unless clearly necessary.

Breast-feeding

It is not known whether doxorubicin hydrochloride is excreted in human milk. Because many medicinal products, including anthracyclines, are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants, therefore mothers must discontinue breast-feeding prior to beginning doxorubicin hydrochloride treatment. Health experts recommend that HIV infected women do not breast-feed their infants under any circumstances in order to avoid transmission of HIV.

Fertility

The effect of doxorubicin hydrochloride on human fertility has not been evaluated (see section 5.3).

4.7. Effects on ability to drive and use machines

Doxorubicin hydrochloride has no or negligible influence on the ability to drive and use machines. However, in clinical trials to date, dizziness and somnolence were associated infrequently (<5%) with the administration of doxorubicin hydrochloride. Patients who suffer from these effects must avoid driving and operating machinery.

4.8. Undesirable effects

Summary of the safety profile

The most frequent adverse reactions (≥20%) were neutropaenia, nausea, leukopaenia, anaemia, and fatigue. Severe adverse reactions (Grade ¾ adverse reactions occurring in ≥2% of patients) were neutropaenia, PPE, leukopaenia, lymphopaenia, anaemia, thrombocytopaenia, stomatitis, fatigue, diarrhoea, vomiting, nausea, pyrexia, dyspnoea, and pneumonia. Less frequently reported severe adverse reactions included Pneumocystis jirovecii pneumonia, abdominal pain, cytomegalovirus infection including cytomegalovirus chorioretinitis, asthenia, cardiac arrest, cardiac failure, cardiac failure congestive, pulmonary embolism, thrombophlebitis, venous thrombosis, anaphylactic reaction, anaphylactoid reaction, toxic epidermal necrolysis, and Stevens-Johnson syndrome.

Tabulated list of adverse reactions

Table 5 summarises the adverse drug reactions that occurred in patients receiving Celdoxome pegylated liposomal in 4,231 patients for the treatment of breast cancer, ovarian cancer, multiple myeloma, and AIDS-related KS. Post-marketing adverse reactions are also included, as indicated by “b”. Frequencies are defined as very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1 000 to <1/100), rare (≥1/10 000 to <1/1 000), very rare (<1/10 000) and not known (frequency cannot be estimated from the available data). Within each frequency grouping, where relevant, adverse reactions are presented in order of decreasing seriousness.

Table 5. Adverse reactions in patients treated with Celdoxome pegylated liposomal:

System organclass Frequency all grades Adverse drug reaction
Infections and
infestations
Common Sepsis
Pneumonia
Pneumocystis jirovecii pneumonia
Cytomegalovirus infection
includingcytomegalovirus
chorioretinitis
Mycobacterium avium complex
infection
Candidiasis
Herpes zoster
Urinary tract infection
Infection
Upper respiratory tract infection
Oral candidiasis
Folliculitis
Pharyngitis
Nasopharyngitis
Uncommon Herpes simplex
Fungal infection
Rare Opportunistic infection (including
Aspergillus,Histoplasma,
Isospora,
Legionella, Microsporidium,
Salmonella, Staphylococcus,
Toxoplasma, Tuberculosis
)a
Neoplasms benign,
malignant and
unspecified (including
cystsand polyps)
Not known Acute myeloid leukaemiab
Myelodysplastic syndromeb
Oral neoplasmb
Blood and lymphatic
system disorders
Very common Leukopaenia
Neutropaenia
Lymphopaenia
Anaemia (including hypochromic)
Common Thrombocytopaenia
Febrile neutropaenia
Uncommon Pancytopaenia
Thrombocytosis
Rare Bone marrow failure
Immune system
disorders
Uncommon Hypersensitivity
Anaphylactic reaction
Rare Anaphylactoid reaction
Metabolism andnutrition
disorders
Very common Decreased appetite
Common Cachexia
Dehydration
Hypokalaemia
Hyponatraemia
Hypocalcaemia
Uncommon Hyperkalaemia
Hypomagnesaemia
Psychiatric
disorders
Common Confusional state
Anxiety
Depression
Insomnia
Nervous system
disorders
Common Neuropathy peripheral
Peripheral sensory neuropathy
Neuralgia
Paraesthesia
Hypoaesthesia
Dysgeusia
Headache
Lethargy
Dizziness
Uncommon Polyneuropathy
Convulsion
Syncope
Dysaesthesia
Somnolence
Eye disorders Common Conjunctivitis
Uncommon Vision blurred
Lacrimation increased
Rare Retinitis
Cardiac disordersa Common Tachycardia
Uncommon Palpitations
Cardiac arrest
Cardiac failure
Cardiac failure congestive
Cardiomyopathy
Cardiotoxicity
Rare Ventricular arrhythmia
Bundle branch block right
Conduction disorder
Atrioventricular block
Cyanosis
Vascular
disorders
Common Hypertension
Hypotension
Flushing
Uncommon Pulmonary embolism
Infusion site necrosis (including
soft tissuenecrosis and skin
necrosis)
Phlebitis
Orthostatic hypotension
Rare Thrombophlebitis
Venous thrombosis
Vasodilatation
Respiratory,thoracic
and mediastinal
disorders
CommonDyspnoea
Dyspnoea exertional
Epistaxis
Cough
Uncommon Asthma
Chest discomfort
Rare Throat tightness
Gastrointestinal
disorders
Very common Stomatitis
Nausea
Vomiting
Diarrhoea
Constipation
Common Gastritis
Aphthous stomatitis
Mouth ulceration
Dyspepsia
Dysphagia
Oesophagitis
Abdominal pain
Abdominal pain upper
Oral pain
Dry mouth
Uncommon Flatulence
Gingivitis
Rare Glossitis
Lip ulceration
Skin and subcutaneous
tissue disorders
Very common Palmar plantar erythrodysaesthesia
syndromea
Rash (including erythematous,
maculo-papular,and papular)
Alopecia
Common Skin exfoliation
Blister
Dry skin
Erythema
Pruritus
Hyperhidrosis
Skin hyperpigmentation
Uncommon Dermatitis
Dermatitis exfoliative
Acne
Skin ulcer
Dermatitis allergic
Urticaria
Skin discolouration
Petechiae
Pigmentation disorder
Nail disorder
Rare Toxic epidermal necrolysis
Erythema multiforme
Dermatitis bullous
Lichenoid keratosis
Not known Stevens-Johnson syndromeb
Musculoskeletaland
connective tissue
disorders
Very commonMusculoskeletal pain (including
musculoskeletal
chest pain, back pain, pain in extremity)
Common Muscle spasms
Myalgia
Arthralgia
Bone pain
Uncommon Muscular weakness
Renal and urinary
disorders
Common Dysuria
Reproductive
disorders
Uncommon Breast pain
Rare Vaginal infection
Scrotal erythema
General disorders and
administrationsite
conditions
Very common Pyrexia
Fatigue
Common Infusion-related reaction
Pain
Chest pain
Influenza-like illness
Chills
Mucosal inflammation
Asthenia
Malaise
Oedema
Oedema peripheral
Uncommon Administration site extravasation
Injection site reaction
Face oedema
Hyperthermia
Rare Mucous membrane disorder
Investigations Common Weight decreased
Uncommon Ejection fraction decreased
Rare Liver function test abnormal
(including Blood bilirubin increased,
Alanine aminotransferase increased
and Aspartate aminotransferase
increased)
Blood creatinine increased
Injury, poisoningand
procedural complications
Uncommon Radiation recall phenomenona

a See "Description of selected adverse reactions"
b Post-marketing adverse reaction

Description of selected adverse reactions

Palmar plantar erythrodysaesthesia

The most common undesirable effect reported in breast/ovarian clinical trials was palmar-plantar erythrodysesthesia (PPE). The overall incidence of PPE reported was 41.3% and 51.1% in the ovarian and breast clinical trials, respectively. These effects were mostly mild, with severe (grade 3) cases reported in 16.3% and 19.6% of patients. The reported incidence of life-threatening (grade 4) cases was <1%. PPE infrequently resulted in permanent treatment discontinuation (1.9% and 10.8%). PPE was reported in 16% of multiple myeloma patients treated with Celdoxome pegylated liposomal plus bortezomib combination therapy. Grade 3 PPE was reported in 5% of patients. No grade 4 PPE was reported. The rate of PPE was substantially lower in the AIDS-KS population (1.3% all grade, 0.4% grade 3 PPE, no grade 4 PPE). See section 4.4.

Opportunistic infections

Respiratory undesirable effects commonly occurred in clinical trials of liposomal doxorubicin and may be related to opportunistic infections (OI’s) in the AIDS population. Opportunistic infections are observed in KS patients after administration of liposomal doxorubicin, and are frequently observed in patients with HIV-induced immunodeficiency. The most frequently observed OI’s in clinical trials were candidiasis, cytomegalovirus, herpes simplex, Pneumocystis jirovecii pneumonia, and mycobacterium avium complex.

Cardiac toxicity

An increased incidence of congestive heart failure is associated with doxorubicin therapy at cumulative lifetime doses > 450 mg/m² or at lower doses for patients with cardiac risk factors. Endomyocardial biopsies on nine of ten AIDS-KS patients receiving cumulative doses of liposomal doxorubicin greater than 460 mg/m² indicate no evidence of anthracycline-induced cardiomyopathy. The recommended dose of Celdoxome pegylated liposomal for AIDS-KS patients is 20 mg/m² every two-to-three weeks. The cumulative dose at which cardiotoxicity would become a concern for these AIDS-KS patients (>400 mg/m²) would require more than 20 courses of Celdoxome pegylated liposomal therapy over 40 to 60 weeks.

In addition, endomyocardial biopsies were performed in 8 solid tumour patients with cumulative anthracycline doses of 509 mg/m² – 1,680 mg/m². The range of Billingham cardiotoxicity scores was grades 0-1.5. These grading scores are consistent with no or mild cardiac toxicity.

In the pivotal phase III trial versus doxorubicin, 58/509 (11.4%) randomised subjects (10 treated with liposomal doxorubicin at a dose of 50 mg/m²/every 4 weeks versus 48 treated with doxorubicin at a dose of 60 mg/m²/every 3 weeks) met the protocol-defined criteria for cardiac toxicity during treatment and/or follow-up. Cardiac toxicity was defined as a decrease of 20 points or greater from baseline if the resting LVEF remained in the normal range or a decrease of 10 points or greater if the LVEF became abnormal (less than the lower limit for normal). None of the 10 liposomal doxorubicintreated subjects who had cardiac toxicity by LVEF criteria developed signs and symptoms of CHF. In contrast, 10 of 48 doxorubicin subjects who had cardiac toxicity by LVEF criteria also developed signs and symptoms of CHF.

In patients with solid tumours, including a subset of patients with breast and ovarian cancers, treated at a dose of 50 mg/m²/cycle with lifetime cumulative anthracycline doses up to 1 532 mg/m², the incidence of clinically significant cardiac dysfunction was low. Of the 418 patients treated with liposomal doxorubicin 50 mg/m²/cycle, and having a baseline measurement of left ventricular ejection fraction (LVEF) and at least one follow-up measurement assessed by MUGA scan, 88 patients had a cumulative anthracycline dose of >400 mg/m², an exposure level associated with an increased risk of cardiovascular toxicity with conventional doxorubicin. Only 13 of these 88 patients (15%) had at least one clinically significant change in their LVEF, defined as an LVEF value less than 45% or a decrease of at least 20 points from baseline. Furthermore, only 1 patient (cumulative anthracycline dose of 944 mg/m²), discontinued study treatment because of clinical symptoms of congestive heart failure.

Radiation recall phenomenon

Recall of skin reaction due to prior radiotherapy has occurred uncommonly with liposomal doxorubicin administration.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

6.2. Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.